大麻公司 Tilray、Canopy Growth、Cronos 和 SNDL 的股价飙升 67.5%。 Cannabis companies Tilray, Canopy Growth, Cronos, and SNDL's shares surge up to 67.5% .

据报道，美国缉毒局 (DEA) 即将重新将大麻从目前的附表 I 分类中剔除，大麻公司 Tilray、Canopy Growth、Cronos 和 SNDL 的股价周二飙升 67.5%。 Cannabis companies Tilray, Canopy Growth, Cronos, and SNDL saw shares surge up to 67.5% on Tuesday, following reports that the U.S. Drug Enforcement Agency (DEA) is set to reschedule marijuana from its current Schedule I classification. 美国卫生与公众服务部（HHS）历史性建议将大麻重新归类为三级毒品，这可能会为美国大麻公司带来巨大的经济利益，尽管这对在美国证券交易所交易的加拿大公司的影响尚不确定。 The historic recommendation by the U.S. Department of Health and Human Services (HHS) to reclassify marijuana as a Schedule III drug could bring significant financial benefits for U.S. cannabis companies, although the impact on Canadian companies trading on U.S. stock exchanges is uncertain.